These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 39103830)

  • 1. Metrnl: a promising biomarker and therapeutic target for cardiovascular and metabolic diseases.
    Dong WS; Hu C; Hu M; Gao YP; Hu YX; Li K; Ye YJ; Zhang X
    Cell Commun Signal; 2024 Aug; 22(1):389. PubMed ID: 39103830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibronectin type III domain-containing 5 in cardiovascular and metabolic diseases: a promising biomarker and therapeutic target.
    Zhang X; Hu C; Wu HM; Ma ZG; Tang QZ
    Acta Pharmacol Sin; 2021 Sep; 42(9):1390-1400. PubMed ID: 33214697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of the secreted protein Metrnl in human diseases.
    Miao ZW; Hu WJ; Li ZY; Miao CY
    Acta Pharmacol Sin; 2020 Dec; 41(12):1525-1530. PubMed ID: 32999412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developmental endothelial locus-1 in cardiovascular and metabolic diseases: A promising biomarker and therapeutic target.
    Zhao M; Zheng Z; Li C; Wan J; Wang M
    Front Immunol; 2022; 13():1053175. PubMed ID: 36518760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meteorin-like protein (Metrnl): A metabolic syndrome biomarker and an exercise mediator.
    Alizadeh H
    Cytokine; 2022 Sep; 157():155952. PubMed ID: 35780711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meteorin-like/Metrnl, a novel secreted protein implicated in inflammation, immunology, and metabolism: A comprehensive review of preclinical and clinical studies.
    Li Z; Gao Z; Sun T; Zhang S; Yang S; Zheng M; Shen H
    Front Immunol; 2023; 14():1098570. PubMed ID: 36911663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sortilin and Its Multiple Roles in Cardiovascular and Metabolic Diseases.
    Goettsch C; Kjolby M; Aikawa E
    Arterioscler Thromb Vasc Biol; 2018 Jan; 38(1):19-25. PubMed ID: 29191923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydrogen Therapy in Cardiovascular and Metabolic Diseases: from Bench to Bedside.
    Zhang Y; Tan S; Xu J; Wang T
    Cell Physiol Biochem; 2018; 47(1):1-10. PubMed ID: 29763888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging therapeutic potential of glycine in cardiometabolic diseases: dual benefits in lipid and glucose metabolism.
    Rom O; Villacorta L; Zhang J; Chen YE; Aviram M
    Curr Opin Lipidol; 2018 Oct; 29(5):428-432. PubMed ID: 30153136
    [No Abstract]   [Full Text] [Related]  

  • 10. Natriuretic Peptides and Cardiometabolic Health.
    Gupta DK; Wang TJ
    Circ J; 2015; 79(8):1647-55. PubMed ID: 26103984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Transient Receptor Potential Channels in Cardiometabolic Diseases and Myocardial Ischemia Reperfusion Injury.
    Ma J; Yang L; Ma Y; Wang X; Ren J; Yang J
    Curr Drug Targets; 2017; 18(15):1733-1745. PubMed ID: 26477459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PPARs as targets for metabolic and cardiovascular diseases.
    Cheng PT; Mukherjee R
    Mini Rev Med Chem; 2005 Aug; 5(8):741-53. PubMed ID: 16101410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The role of adipokines in formation of lipid and carbohydrate metabolic disorders in patients with cardiovascular disease].
    Kravchun P; Kadykova O; Gabisoniia T
    Georgian Med News; 2012 Dec; (213):26-31. PubMed ID: 23293229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Apelinergic System in Cardiometabolic Disease.
    Guo R; Rogers O; Nair S
    Curr Drug Targets; 2017; 18(15):1785-1791. PubMed ID: 27296311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine.
    Tan H; Yue T; Chen Z; Wu W; Xu S; Weng J
    Int J Biol Sci; 2023; 19(1):66-88. PubMed ID: 36594101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of melatonin on cardiovascular risk factors and metabolic syndrome: a comprehensive review.
    Imenshahidi M; Karimi G; Hosseinzadeh H
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Apr; 393(4):521-536. PubMed ID: 32002576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of low serum Meteorin like (Metrnl) concentrations with worsening of glucose tolerance, impaired endothelial function and atherosclerosis.
    El-Ashmawy HM; Selim FO; Hosny TAM; Almassry HN
    Diabetes Res Clin Pract; 2019 Apr; 150():57-63. PubMed ID: 30825562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metrnl Alleviates Lipid Accumulation by Modulating Mitochondrial Homeostasis in Diabetic Nephropathy.
    Zhou Y; Liu L; Jin B; Wu Y; Xu L; Chang X; Hu L; Wang G; Huang Y; Song L; Zhang T; Wang Y; Xiao Y; Zhang F; Shi M; Liu L; Wang T; Yan R; Guo B
    Diabetes; 2023 May; 72(5):611-626. PubMed ID: 36812572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atrial Natriuretic Peptide: A Molecular Target of Novel Therapeutic Approaches to Cardio-Metabolic Disease.
    Cannone V; Cabassi A; Volpi R; Burnett JC;
    Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31269783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pigment Epithelium-Derived Factor: A Novel Therapeutic Target for Cardiometabolic Diseases and Related Complications.
    Yamagishi SI; Matsui T
    Curr Med Chem; 2018; 25(13):1480-1500. PubMed ID: 28595552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.